(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

EVOLVE BIOLOGICS

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: United States

Quick snapshot

EVOLVE BIOLOGICS

ST13

US500000087717949

Class

5, 37, 40, 41, 42

Filing

87717949

Registration

6297748

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

54

Latest update

03/24/2026

Trademark type

Combined

Nice classes

5, 37, 40, 41, 42

Filing date

12/12/2017

Registration date

03/23/2021

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

03/23/2021

Last transaction

03/24/2026

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use, Foreign priority

Drawing code

5

Owner type

03

Owner location

Mississauga, Ontario, CA

Examiner

MORENO, PAUL A

Law office

L30

Current location

TMEG LAW OFFICE 103

Mark description

The mark consists of the word "EVOLVE" in stylized lettering with the "V" forming into the "O" with the word "BIOLOGICS" underneath the letters "LVE" in stylized format.

Holders and representatives

Holders

EVOLVE BIOLOGICS INC.
Therapure Biopharma Inc.

Representatives

Christopher J. Schulte MERCHANT & GOULD P.C.

Technical classification

Nice Classes

Class 5Class 37Class 40Class 41Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Biologics from human bloodhuman blood plasmafractionated human blood plasmacryopastecryoprecipitate for human clinical useplasma protein fractionsserum albuminimmunoglobulinscoagulation factorsantihemophilic factorsclotting factorsenzymescoenzymescoactivatorsinhibitorsstructural proteins; resinsfor medical usepolysaccharide beads cross-linked to ligands for capturing proteins from human bloodhuman blood plasmafractionated human blood plasmacryopastecryoprecipitate using chromatographic methods

Class 37

Construction of biotechbiopharmaceutical and plasma manufacturing facilities relevant to the manufacturing of biologics from human bloodhuman blood plasmafractionated human blood plasmacryopastecryoprecipitate; consulting services concerning construction of biotech; Consulting services concerning building construction of biotech facilities

Class 40

Contract manufacturing services for others for biologics from human bloodhuman blood plasmafractionated human blood plasmacryopastecryoprecipitate for research and developmentclinical use; consulting services concerning manufacturing of biologics

Class 41

Educational servicesdesigningarrangingconducting training programs for research and developmentmanufacturing of biologicsdesignconstructionuse of chromatography equipment

Class 42

Development of pharmaceutical preparations and medicinesdevelopment services for others for the capture of biologics from human bloodhuman blood plasmafractionated human blood plasmacryopastecryoprecipitate for research and development; consulting services for others concerning the capture of biologics from human bloodhuman blood plasmafractionated human blood plasmacryopastecryoprecipitate for research and developmentdesign and construction of chromatography equipmentdesign of biotechbiopharmaceutical and plasma manufacturing facilitiesscientific research and evaluationengineering; Design of biotechbiopharmaceutical and plasma manufacturing facilities relevant to the manufacturing of biolotics from human bloodhuman blood plasmafractionated human blood plasmacryopastecryoprecipitate

Publications

History of USPTO decisions and trademark events.

54 publications found

REM1

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

03/23/2026

CORV

REVIEW OF CORRESPONDENCE COMPLETE - INFORMATION MADE OF RECORD

07/07/2021

COC.

CORRECTION UNDER SECTION 7 - PROCESSED

07/07/2021

PARI

TEAS VOLUNTARY AMENDMENT RECEIVED

07/01/2021

ES7R

TEAS SECTION 7 REQUEST RECEIVED

04/19/2021

R.PR

REGISTERED-PRINCIPAL REGISTER

03/23/2021

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

01/05/2021

PUBO

PUBLISHED FOR OPPOSITION

01/05/2021

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

12/16/2020

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

12/01/2020

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

11/26/2020

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

11/25/2020

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

11/25/2020

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

11/25/2020

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

07/06/2020

GNRT

NON-FINAL ACTION E-MAILED

07/06/2020

CNRT

NON-FINAL ACTION WRITTEN

07/06/2020

LOPT

LETTER OF PROTEST EVIDENCE FORWARDED

06/25/2020

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

02/12/2020

GNRT

NON-FINAL ACTION E-MAILED

02/12/2020

CNRT

NON-FINAL ACTION WRITTEN

02/12/2020

ZZZX

PREVIOUS ALLOWANCE COUNT WITHDRAWN

01/28/2020

PBCR

WITHDRAWN FROM PUB - OG REVIEW QUERY

01/14/2020

ASCK

ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY

01/01/2020

FIXD

ELECTRONIC RECORD REVIEW COMPLETE

12/30/2019

ERRR

ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED

12/27/2019

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

12/19/2019

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

12/18/2019

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

12/18/2019

ERSI

TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED

12/13/2019

ASCK

ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY

11/27/2019

ASCK

ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY

10/30/2019

GNS2

NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED

06/19/2019

GNSI

INQUIRY TO SUSPENSION E-MAILED

06/19/2019

CNSI

SUSPENSION INQUIRY WRITTEN

06/19/2019

GNS3

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

11/30/2018

GNSL

LETTER OF SUSPENSION E-MAILED

11/30/2018

CNSL

SUSPENSION LETTER WRITTEN

11/30/2018

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

11/07/2018

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

11/07/2018

ERSI

TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED

10/30/2018

GNS3

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

05/03/2018

GNSL

LETTER OF SUSPENSION E-MAILED

05/03/2018

CNSL

SUSPENSION LETTER WRITTEN

05/03/2018

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

05/03/2018

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

05/03/2018

ALIE

ASSIGNED TO LIE

05/01/2018

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

04/24/2018

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

02/16/2018

GNRT

NON-FINAL ACTION E-MAILED

02/16/2018

CNRT

NON-FINAL ACTION WRITTEN

02/16/2018

DOCK

ASSIGNED TO EXAMINER

02/14/2018

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

12/22/2017

NWAP

NEW APPLICATION ENTERED

12/15/2017

Continuous trademark protection

Get notified about every new filing that threatens EVOLVE BIOLOGICS or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.